BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J. Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users. CNS Drugs 2014;28:361-72. [DOI: 10.1007/s40263-014-0150-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Asakura S, Shiotani M, Gauvin DV, Fujiwara A, Ueno T, Bower N, Beuckmann CT, Moline M. Nonclinical evaluation of abuse liability of the dual orexin receptor antagonist lemborexant. Regul Toxicol Pharmacol 2021;127:105053. [PMID: 34619288 DOI: 10.1016/j.yrtph.2021.105053] [Reference Citation Analysis]
2 Born S, Gauvin DV, Mukherjee S, Briscoe R. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 2017;86:181-92. [PMID: 28279667 DOI: 10.1016/j.yrtph.2017.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
3 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
4 Manworren JR, Hajduk J, Hill JN, Raad AA, Manworren RCB. Adolescents' Understanding of Opioid-Induced Euphoria Measures and Proposed Measurement Revisions. J Psychoactive Drugs 2021;:1-11. [PMID: 34355666 DOI: 10.1080/02791072.2021.1953642] [Reference Citation Analysis]
5 James MH, Mahler SV, Moorman DE, Aston-Jones G. A Decade of Orexin/Hypocretin and Addiction: Where Are We Now? Curr Top Behav Neurosci 2017;33:247-81. [PMID: 28012090 DOI: 10.1007/7854_2016_57] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 16.0] [Reference Citation Analysis]
6 Ufer M, Kelsh D, Schoedel KA, Dingemanse J. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep 2021:zsab224. [PMID: 34480579 DOI: 10.1093/sleep/zsab224] [Reference Citation Analysis]
7 Fattore L, Diana M. Drug addiction: An affective-cognitive disorder in need of a cure. Neuroscience & Biobehavioral Reviews 2016;65:341-61. [DOI: 10.1016/j.neubiorev.2016.04.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]